Skip to main content

Caissa Capital Management ltd.'s Form 4 filing

Avalo Therapeutics, Inc. (AVTX) · filed May 24, 2023

Accession no.
0001929354-23-000010
Filed
May 24, 2023
Trade date
May 24, 2023
Filing delay
Same day
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions. Open-market purchases total $26.8K. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Caissa Capital Management ltd.CIK 000192935410% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 24, 2023Common StockPPurchaseAcquired+3,481$3.01F2+$10,477.811,377,181Indirect
May 24, 2023Common StockPPurchaseAcquired+5,519$2.96F3+$16,336.241,382,700Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.0 to $3.01, inclusive.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.92 to $3.03, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)